Rizou Stavroula, Aravantinos Leon, Paganas Aristofanis, Ballas Michael, Lyritis George P
Hellenic Osteoporosis Foundation, Athens, Greece.
2 Department of Obstetrics and Gynecology, University of Athens, Aretaieion Hospital, Athens, Greece.
J Frailty Sarcopenia Falls. 2017 Dec 1;2(4):78-82. doi: 10.22540/JFSF-02-078. eCollection 2017 Dec.
A study to retrospectively assess the decision to implement treatment for osteoporosis based on Greek version of FRAX tool.
The study population was 1000 postmenopausal women aged 45 or above, excluding those with medical conditions demanding specific osteoporosis management. Data were collected regarding their medical history and additionally, risk factors incorporated in FRAX questionnaire. FRAX score was estimated at the time of the anti-osteoporotic treatment initiation.
The mean age of the study sample was 58.5±8.79 years. 46.8% of the participating osteopenic women had initiated treatment for osteoporosis at their first consultation while the 80.6% met the current national intervention threshold of FRAX tool.
Stemming from our results there is an indication that women who are borderline eligible for treatment and seek consultation for osteoporosis are likely to be given treatment regardless of the potential benefit. One cannot ignore the fact that a clinician's good clinical judgment is of the utmost importance and under no circumstances can be replaced by any prognostic assessment tool.
一项回顾性研究，旨在基于FRAX工具的希腊语版本评估骨质疏松症治疗决策。
研究人群为1000名45岁及以上的绝经后女性，排除患有需要特定骨质疏松症管理的疾病的女性。收集她们的病史数据，此外，还收集FRAX问卷中包含的风险因素。在开始抗骨质疏松治疗时估算FRAX评分。
研究样本的平均年龄为58.5±8.79岁。46.8%的参与研究的骨量减少女性在首次咨询时就开始了骨质疏松症治疗，而80.6%的女性达到了FRAX工具当前的国家干预阈值。
从我们的结果来看，有迹象表明，处于治疗边缘且寻求骨质疏松症咨询的女性无论潜在益处如何都可能接受治疗。不能忽视这样一个事实，即临床医生良好的临床判断至关重要，在任何情况下都不能被任何预后评估工具所取代。
